SG11201903674YA - Messenger ribonucleic acids for enhancing immune responses and methods of use thereof - Google Patents

Messenger ribonucleic acids for enhancing immune responses and methods of use thereof

Info

Publication number
SG11201903674YA
SG11201903674YA SG11201903674YA SG11201903674YA SG11201903674YA SG 11201903674Y A SG11201903674Y A SG 11201903674YA SG 11201903674Y A SG11201903674Y A SG 11201903674YA SG 11201903674Y A SG11201903674Y A SG 11201903674YA SG 11201903674Y A SG11201903674Y A SG 11201903674YA
Authority
SG
Singapore
Prior art keywords
international
immune responses
publication
cambridge
pct
Prior art date
Application number
SG11201903674YA
Other languages
English (en)
Inventor
Eric Huang
Sze-Wah Tse
Jared Iacovelli
Kristine Mckinney
Kristen Hopson
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of SG11201903674YA publication Critical patent/SG11201903674YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201903674YA 2016-10-26 2017-10-26 Messenger ribonucleic acids for enhancing immune responses and methods of use thereof SG11201903674YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662412933P 2016-10-26 2016-10-26
US201762467034P 2017-03-03 2017-03-03
US201762490522P 2017-04-26 2017-04-26
US201762558206P 2017-09-13 2017-09-13
PCT/US2017/058585 WO2018081459A1 (en) 2016-10-26 2017-10-26 Messenger ribonucleic acids for enhancing immune responses and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201903674YA true SG11201903674YA (en) 2019-05-30

Family

ID=60570181

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903674YA SG11201903674YA (en) 2016-10-26 2017-10-26 Messenger ribonucleic acids for enhancing immune responses and methods of use thereof

Country Status (13)

Country Link
US (3) US20180311343A1 (enrdf_load_stackoverflow)
EP (1) EP3532070A1 (enrdf_load_stackoverflow)
JP (2) JP2019532657A (enrdf_load_stackoverflow)
KR (1) KR20190086681A (enrdf_load_stackoverflow)
CN (1) CN110402145A (enrdf_load_stackoverflow)
AU (1) AU2017347837A1 (enrdf_load_stackoverflow)
BR (1) BR112019008369A2 (enrdf_load_stackoverflow)
CA (1) CA3042015A1 (enrdf_load_stackoverflow)
IL (1) IL266222A (enrdf_load_stackoverflow)
MX (1) MX2019004810A (enrdf_load_stackoverflow)
RU (1) RU2765874C2 (enrdf_load_stackoverflow)
SG (1) SG11201903674YA (enrdf_load_stackoverflow)
WO (1) WO2018081459A1 (enrdf_load_stackoverflow)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200158T1 (it) 2014-04-23 2022-05-12 Modernatx Inc Vaccini ad acidi nucleici
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
AU2016342371B2 (en) 2015-10-22 2023-05-11 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
CN109640962B (zh) 2016-05-18 2022-07-19 摩登纳特斯有限公司 编码松弛素的多核苷酸
US11202793B2 (en) 2016-09-14 2021-12-21 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
WO2018140733A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
RU2768829C2 (ru) * 2017-02-01 2022-03-24 МОДЕРНАТиЭкс, ИНК. Противораковые рнк-вакцины
CA3051252A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018213789A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Modified messenger rna comprising functional rna elements
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
WO2019035901A1 (en) * 2017-08-15 2019-02-21 University Of Miami COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
JP2021511016A (ja) 2017-12-21 2021-05-06 ベースクリック ゲーエムベーハー クリック修飾ｍＲＮＡ
EP3740198A4 (en) * 2018-01-18 2023-08-09 Fred Hutchinson Cancer Center MODIFICATION OF INFLAMMATORY STATES OF IMMUNE CELLS IN VIVO BY MODULATION OF CELL ACTIVATION STATES
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA VACCINES
WO2019152557A1 (en) * 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
CA3097850A1 (en) * 2018-03-26 2019-10-03 University Of Miami Recombinant viral vector and uses thereof
US20210163928A1 (en) * 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
AU2019277361B2 (en) * 2018-05-30 2025-04-24 Translate Bio, Inc. Messenger RNA vaccines and uses thereof
IL319091A (en) 2018-06-06 2025-04-01 Massachusetts Inst Technology Circular RNA for translation in eukaryotic cells
MX2021000165A (es) 2018-07-11 2021-05-28 Actym Therapeutics Inc Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas.
WO2020028743A1 (en) * 2018-08-03 2020-02-06 Board Of Trustees Of Michigan State University Compositions of sting variants, combinations thereof, and methods for inducing and enhancing an immune response against infections, diseases, and disorders
US20220002730A1 (en) * 2018-08-24 2022-01-06 City Of Hope Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
MA53652A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg de haute pureté et leurs utilisations
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
CA3123595A1 (en) * 2018-12-21 2020-06-25 Tiba Biotech Llc Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
CN109762895A (zh) * 2019-01-07 2019-05-17 中国医学科学院北京协和医院 miR-146a在制备诊断激素性股骨头坏死产品中的应用
EP3683229A1 (en) * 2019-01-21 2020-07-22 Charité - Universitätsmedizin Berlin Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
CN113748124A (zh) 2019-02-27 2021-12-03 阿克蒂姆治疗有限公司 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
EP3946434A1 (en) 2019-04-02 2022-02-09 Immunetune B.V. Immune-stimulatory compositions and use thereof
SG11202112922WA (en) 2019-05-22 2021-12-30 Massachusetts Inst Technology Circular rna compositions and methods
AU2020299636A1 (en) * 2019-07-03 2022-02-24 The Walter And Eliza Hall Institute Of Medical Research Compositions and methods of use
WO2021062037A1 (en) * 2019-09-24 2021-04-01 Auburn University Phage-peptide constructs for stimulation of an anti-cancer immune response against cd47
CN114728176A (zh) * 2019-10-09 2022-07-08 川斯勒佰尔公司 信使rna的组合物、方法和使用
WO2021081296A1 (en) * 2019-10-24 2021-04-29 Joshua Labaer Novel antibodies for detecting epstein barr virus-positive gastric cancer
CA3177479A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
EP4061424A4 (en) * 2019-11-14 2023-01-25 Bogazici Universitesi ASC STAINS USED IN CANCER IMMUNOTHERAPY
TW202131945A (zh) * 2019-11-15 2021-09-01 日商第一三共股份有限公司 封入HPV mRNA之核酸脂質粒子疫苗
WO2021108025A1 (en) * 2019-11-26 2021-06-03 Massachusetts Institute Of Technology Cell-based cancer vaccines and cancer therapies
ES2961245T3 (es) 2019-12-04 2024-03-11 Orna Therapeutics Inc Composiciones y métodos de ARN circular
EP4075980B1 (en) 2019-12-18 2025-07-23 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
CN115297868B (zh) * 2020-02-21 2024-04-12 联合治疗公司 用于编码核糖核酸的器官保护性表达和调节的组合物及方法
WO2021168266A1 (en) * 2020-02-21 2021-08-26 Temple University - Of The Commonwealth System Of Higher Education Eradication of merkel cell polyomavirus
WO2021197589A1 (en) * 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
CN113521269A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
WO2021216647A1 (en) * 2020-04-22 2021-10-28 Nutcracker Therapeutics, Inc. Mrna treatment nanoparticles
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
IL298993A (en) * 2020-07-07 2023-02-01 BioNTech SE Therapeutic rna for hpv-positive cancer
CN116209771A (zh) * 2020-07-31 2023-06-02 联合治疗公司 用于改善疫苗接种的组合物和方法
CA3187258A1 (en) * 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
AU2021360796A1 (en) * 2020-10-14 2023-06-08 RNAimmune, Inc. PAN-RAS mRNA CANCER VACCINES
GB202017119D0 (en) * 2020-10-28 2020-12-09 Oxford Vacmedix Uk Ltd Polypeptides for cancer treatment
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CA3202227A1 (en) * 2020-11-20 2022-05-27 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
GB202020063D0 (en) * 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
WO2022140588A1 (en) * 2020-12-23 2022-06-30 Kernal Biologics, Inc. Constitutively active payloads
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US20240082378A1 (en) * 2021-01-15 2024-03-14 University Of Rochester Staphylococcus aureus Antigen-Based Nucleic Acid Vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CA3214085A1 (en) * 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
TW202307211A (zh) * 2021-05-19 2023-02-16 日商第一三共股份有限公司 Hpv感染症疫苗
US20240269267A1 (en) * 2021-06-03 2024-08-15 The Wistar Institute Of Anatomy And Biology Synthetic dna vaccine immunogenic improvements
US20240358821A1 (en) * 2021-07-06 2024-10-31 The Trustees Of The University Of Pennsylvania P7 Containing Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus
CN113616793B (zh) * 2021-08-20 2023-07-04 南方海洋科学与工程广东省实验室(湛江) Traf6抑制剂在作为和/或制备铁死亡诱导剂中的应用
WO2023076131A2 (en) * 2021-10-25 2023-05-04 The Regents Of The University Of California Kaposi sarcoma associated herpesvirus gene function
JP2024542173A (ja) 2021-11-09 2024-11-13 アクティム・セラピューティクス・インコーポレイテッド マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法
CN113952359A (zh) * 2021-11-19 2022-01-21 大连理工大学盘锦产业技术研究院 顺铂与Tri-1的联合抗肺癌药物组合物及其应用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023125974A1 (zh) * 2021-12-31 2023-07-06 广州国家实验室 mRNA疫苗
CN118829624A (zh) * 2022-01-17 2024-10-22 赛诺菲 脂质化合物及其用途
WO2023159197A1 (en) * 2022-02-18 2023-08-24 Modernatx, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115089588A (zh) * 2022-08-22 2022-09-23 云南大学 达沙布韦作为e3连接酶新型配体构建protac的应用
WO2025087266A1 (en) * 2023-10-23 2025-05-01 Abogen Biosciences (Shanghai) Co., Ltd. Immunomodulatory mrna cassettes, and uses thereof
WO2025087250A1 (en) * 2023-10-23 2025-05-01 Abogen Biosciences (Shanghai) Co., Ltd. Therapeutic mrna cancer vaccine targeting hpv-associated cancers
CN119662655A (zh) * 2023-12-04 2025-03-21 武汉厚先生物医药有限公司 Rna分子及其组合物在肿瘤免疫治疗中的应用
WO2025153053A1 (en) * 2024-01-17 2025-07-24 Abogen Biosciences (Shanghai) Co., Ltd. Composition and methods for inducing antigen specific immunity against kras mutant cells
CN118839285B (zh) * 2024-08-05 2025-03-18 洛阳莱普生信息科技有限公司 基于智能耳标的畜牧生物资产监管方法及系统

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1996010585A1 (en) 1994-09-30 1996-04-11 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
AU2002347035B2 (en) 2001-09-28 2008-04-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Micro-RNA molecules
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
CA2633754C (en) 2006-01-05 2013-06-18 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
EP2522748A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
EP2487240B1 (en) 2006-09-19 2016-11-16 Interpace Diagnostics, LLC Micrornas differentially expressed in pancreatic diseases and uses thereof
ES2425416T3 (es) 2006-11-01 2013-10-15 The Ohio State University Research Foundation Firma de expresión del microARN para predecir la supervivencia y la metástasis en el carcinoma hepatocelular
US20090092974A1 (en) 2006-12-08 2009-04-09 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
WO2008147974A1 (en) 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
HUE029164T2 (hu) * 2007-09-14 2017-02-28 Univ Brussel Vrije Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra
JP2011505143A (ja) 2007-11-30 2011-02-24 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング
US20090263803A1 (en) 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
CN102015027A (zh) 2008-02-28 2011-04-13 俄亥俄州立大学研究基金会 与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009149539A1 (en) * 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN102439169B (zh) 2008-11-13 2014-11-19 复旦大学 用于结肠直肠癌的微rna表达谱分析的组合物和方法
US20120053224A1 (en) 2008-12-10 2012-03-01 Universitat Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
CA2761411A1 (en) 2009-05-08 2010-11-11 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
CN102625696B (zh) 2009-06-10 2015-06-03 阿尔尼拉姆医药品有限公司 改进的脂质制剂
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
WO2012045075A1 (en) 2010-10-01 2012-04-05 Jason Schrum Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS56923B1 (sr) * 2010-10-26 2018-05-31 Univ Friedrich Alexander Er Dendritske ćelije manipulisane nfkb signalnom putanjom
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP2694534B1 (en) 2011-04-08 2018-06-20 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
EP2944961A1 (en) 2011-05-06 2015-11-18 XenTech Markers for cancer prognosis and therapy and methods of use
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
CA2838063C (en) 2011-06-08 2023-07-11 Shire Human Genetic Therapies, Inc. Cleavable lipids
WO2013011378A1 (en) 2011-07-15 2013-01-24 Leo Pharma A/S Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl)
US20150080243A1 (en) 2011-09-01 2015-03-19 Allegro Diagnostics Corp. Methods and compositions for detecting cancer based on mirna expression profiles
WO2013066678A1 (en) 2011-10-26 2013-05-10 Georgetown University Microrna expression profiling of thyroid cancer
CA3165769A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
JP6204930B2 (ja) 2012-03-05 2017-09-27 ユニバーシティ オブ メリーランド，ボルチモア 多価ワクチンによる黄色ブドウ球菌感染症からの保護
CA2868996A1 (en) * 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2014039961A1 (en) * 2012-09-07 2014-03-13 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP4227685A3 (en) 2013-12-03 2024-02-28 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
EP3556353A3 (en) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
SMT202200158T1 (it) * 2014-04-23 2022-05-12 Modernatx Inc Vaccini ad acidi nucleici
SG10201809701TA (en) 2014-05-06 2018-12-28 Targovax Asa Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
EP4148083A1 (en) * 2014-06-25 2023-03-15 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
MX383164B (es) * 2015-04-22 2025-03-13 CureVac SE Composicion que contiene arn para tratamiento de enfermedades tumorales.
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
MA42543A (fr) * 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Also Published As

Publication number Publication date
MX2019004810A (es) 2019-10-15
AU2017347837A1 (en) 2019-06-06
CA3042015A1 (en) 2018-05-03
WO2018081459A9 (en) 2018-11-22
US20250170235A1 (en) 2025-05-29
JP2019532657A (ja) 2019-11-14
WO2018081459A1 (en) 2018-05-03
JP2022184924A (ja) 2022-12-13
RU2019116006A (ru) 2020-11-27
US20200261572A1 (en) 2020-08-20
KR20190086681A (ko) 2019-07-23
IL266222A (en) 2019-06-30
EP3532070A1 (en) 2019-09-04
RU2765874C2 (ru) 2022-02-04
US20180311343A1 (en) 2018-11-01
RU2019116006A3 (enrdf_load_stackoverflow) 2021-07-30
CN110402145A (zh) 2019-11-01
BR112019008369A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201906969PA (en) Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201909949XA (en) Targeted immunotolerance
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201811432WA (en) Rna for cancer therapy
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201809381XA (en) Polynucleotides encoding interleukin-12 (il12) and uses thereof
SG11201901445TA (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use